25 XP   0   0   10

Xbrane Biopharma AB
Buy, Hold or Sell?

Let's analyse Xbrane together

PenkeI guess you are interested in Xbrane Biopharma AB. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Xbrane Biopharma AB. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Xbrane Biopharma AB

I send you an email if I find something interesting about Xbrane Biopharma AB.

Quick analysis of Xbrane (30 sec.)










What can you expect buying and holding a share of Xbrane? (30 sec.)

How much money do you get?

How much money do you get?
kr0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
kr0.65
Expected worth in 1 year
kr-0.31
How sure are you?
32.4%

+ What do you gain per year?

Total Gains per Share
kr-0.96
Return On Investment
-264.9%

For what price can you sell your share?

Current Price per Share
kr0.36
Expected price per share
kr0.2204 - kr3.45
How sure are you?
50%

1. Valuation of Xbrane (5 min.)




Live pricePrice per Share (EOD)

kr0.36

Intrinsic Value Per Share

kr-11.73 - kr-13.58

Total Value Per Share

kr-11.07 - kr-12.93

2. Growth of Xbrane (5 min.)




Is Xbrane growing?

Current yearPrevious yearGrowGrow %
How rich?$15.6m$34.5m-$5.5m-19.2%

How much money is Xbrane making?

Current yearPrevious yearGrowGrow %
Making money-$8.8m-$3.9m-$4.9m-55.6%
Net Profit Margin-161.5%-327.2%--

How much money comes from the company's main activities?

3. Financial Health of Xbrane (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#625 / 1016

Most Revenue
#346 / 1016

Most Profit
#527 / 1016

Most Efficient
#619 / 1016

What can you expect buying and holding a share of Xbrane? (5 min.)

Welcome investor! Xbrane's management wants to use your money to grow the business. In return you get a share of Xbrane.

What can you expect buying and holding a share of Xbrane?

First you should know what it really means to hold a share of Xbrane. And how you can make/lose money.

Speculation

The Price per Share of Xbrane is kr0.364. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Xbrane.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Xbrane, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is kr0.65. Based on the TTM, the Book Value Change Per Share is kr-0.24 per quarter. Based on the YOY, the Book Value Change Per Share is kr-0.01 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is kr0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Xbrane.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 kr% of Price per Sharekr% of Price per Sharekr% of Price per Sharekr% of Price per Sharekr% of Price per Share
Usd Eps-0.05-15.0%-0.03-9.2%-0.01-4.1%-0.02-5.4%-0.01-3.2%
Usd Book Value Change Per Share-0.06-15.2%-0.02-6.0%0.00-0.2%0.000.4%0.000.4%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.06-15.2%-0.02-6.0%0.00-0.2%0.000.4%0.000.4%
Usd Price Per Share0.91-4.57-7.42-6.42-4.87-
Price to Earnings Ratio-4.17--44.66--130.02--96.19--138.59-
Price-to-Total Gains Ratio-16.44-27.39--401.46--161.18--48,672.22-
Price to Book Ratio15.35-37.29-56.72-75.15-82.68-
Price-to-Total Gains Ratio-16.44-27.39--401.46--161.18--48,672.22-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.0331968
Number of shares30123
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.020.00
Usd Total Gains Per Share-0.020.00
Gains per Quarter (30123 shares)-662.2546.11
Gains per Year (30123 shares)-2,648.99184.43
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-2649-26590184174
20-5298-53080369358
30-7947-79570553542
40-10596-106060738726
50-13245-132550922910
60-15894-15904011071094
70-18543-18553012911278
80-21192-21202014751462
90-23841-23851016601646
100-26490-26500018441830

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%1.036.00.02.7%1.036.00.02.7%
Book Value Change Per Share1.03.00.025.0%3.09.00.025.0%7.013.00.035.0%12.023.02.032.4%12.023.02.032.4%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.037.00.0%0.00.037.00.0%
Total Gains per Share1.03.00.025.0%3.09.00.025.0%7.013.00.035.0%12.023.02.032.4%12.023.02.032.4%

Fundamentals of Xbrane

About Xbrane Biopharma AB

Xbrane Biopharma AB (publ), a biotechnology company, develops, manufactures, and sells biosimilars. The company is developing Ximluci, a ranibizumab biosimilar used for the treatment of wet age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults. Its pre-clinical phase products include BIIB801, a biosimilar candidate for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease, and axial spondylitis; Xdivane for skin cancer, lung cancer, renal cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xtrudane for brain cancer, melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; and Xdarzane for multiple melanoma. Xbrane Biopharma AB (publ) was incorporated in 2008 and is headquartered in Solna, Sweden.

Fundamental data was last updated by Penke on 2024-04-04 12:30:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is just able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Xbrane Biopharma AB.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Xbrane earns for each kr1 of revenue.

  • Above 10% is considered healthy but always compare Xbrane to the Biotechnology industry mean.
  • A Net Profit Margin of -235.5% means that kr-2.35 for each kr1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Xbrane Biopharma AB:

  • The MRQ is -235.5%. The company is making a huge loss. -2
  • The TTM is -161.5%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-235.5%TTM-161.5%-74.0%
TTM-161.5%YOY-327.2%+165.7%
TTM-161.5%5Y-841.8%+680.3%
5Y-841.8%10Y-875.6%+33.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-235.5%-197.2%-38.3%
TTM-161.5%-210.4%+48.9%
YOY-327.2%-279.3%-47.9%
5Y-841.8%-436.8%-405.0%
10Y-875.6%-599.3%-276.3%
1.1.2. Return on Assets

Shows how efficient Xbrane is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Xbrane to the Biotechnology industry mean.
  • -24.1% Return on Assets means that Xbrane generated kr-0.24 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Xbrane Biopharma AB:

  • The MRQ is -24.1%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -12.8%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-24.1%TTM-12.8%-11.3%
TTM-12.8%YOY-6.6%-6.3%
TTM-12.8%5Y-11.0%-1.8%
5Y-11.0%10Y-10.2%-0.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-24.1%-13.6%-10.5%
TTM-12.8%-12.9%+0.1%
YOY-6.6%-11.9%+5.3%
5Y-11.0%-14.2%+3.2%
10Y-10.2%-16.2%+6.0%
1.1.3. Return on Equity

Shows how efficient Xbrane is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Xbrane to the Biotechnology industry mean.
  • -91.9% Return on Equity means Xbrane generated kr-0.92 for each kr1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Xbrane Biopharma AB:

  • The MRQ is -91.9%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -38.8%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-91.9%TTM-38.8%-53.2%
TTM-38.8%YOY-11.3%-27.4%
TTM-38.8%5Y-25.2%-13.6%
5Y-25.2%10Y-19.3%-5.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-91.9%-17.0%-74.9%
TTM-38.8%-16.1%-22.7%
YOY-11.3%-15.4%+4.1%
5Y-25.2%-20.0%-5.2%
10Y-19.3%-21.1%+1.8%

1.2. Operating Efficiency of Xbrane Biopharma AB.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Xbrane is operating .

  • Measures how much profit Xbrane makes for each kr1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Xbrane to the Biotechnology industry mean.
  • An Operating Margin of -124.4% means the company generated kr-1.24  for each kr1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Xbrane Biopharma AB:

  • The MRQ is -124.4%. The company is operating very inefficient. -2
  • The TTM is -142.9%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-124.4%TTM-142.9%+18.5%
TTM-142.9%YOY-321.0%+178.1%
TTM-142.9%5Y-827.7%+684.8%
5Y-827.7%10Y-1,385.4%+557.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-124.4%-286.1%+161.7%
TTM-142.9%-224.4%+81.5%
YOY-321.0%-288.4%-32.6%
5Y-827.7%-475.2%-352.5%
10Y-1,385.4%-624.7%-760.7%
1.2.2. Operating Ratio

Measures how efficient Xbrane is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 2.24 means that the operating costs are kr2.24 for each kr1 in net sales.

Let's take a look of the Operating Ratio trends of Xbrane Biopharma AB:

  • The MRQ is 2.244. The company is inefficient in keeping operating costs low. -1
  • The TTM is 2.359. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ2.244TTM2.359-0.114
TTM2.359YOY4.099-1.740
TTM2.3595Y8.660-6.301
5Y8.66010Y9.290-0.630
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.2442.997-0.753
TTM2.3593.247-0.888
YOY4.0993.766+0.333
5Y8.6605.675+2.985
10Y9.2907.857+1.433

1.3. Liquidity of Xbrane Biopharma AB.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Xbrane is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 1.41 means the company has kr1.41 in assets for each kr1 in short-term debts.

Let's take a look of the Current Ratio trends of Xbrane Biopharma AB:

  • The MRQ is 1.414. The company is just able to pay all its short-term debts.
  • The TTM is 1.746. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ1.414TTM1.746-0.332
TTM1.746YOY1.996-0.251
TTM1.7465Y1.889-0.144
5Y1.88910Y2.818-0.929
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.4143.930-2.516
TTM1.7464.251-2.505
YOY1.9965.436-3.440
5Y1.8896.045-4.156
10Y2.8186.363-3.545
1.3.2. Quick Ratio

Measures if Xbrane is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Xbrane to the Biotechnology industry mean.
  • A Quick Ratio of 0.42 means the company can pay off kr0.42 for each kr1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Xbrane Biopharma AB:

  • The MRQ is 0.418. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.824. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.418TTM0.824-0.406
TTM0.824YOY1.038-0.214
TTM0.8245Y1.066-0.242
5Y1.06610Y1.943-0.877
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4183.629-3.211
TTM0.8244.065-3.241
YOY1.0385.397-4.359
5Y1.0665.993-4.927
10Y1.9436.277-4.334

1.4. Solvency of Xbrane Biopharma AB.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Xbrane assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Xbrane to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.74 means that Xbrane assets are financed with 73.8% credit (debt) and the remaining percentage (100% - 73.8%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Xbrane Biopharma AB:

  • The MRQ is 0.738. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.600. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.738TTM0.600+0.138
TTM0.600YOY0.426+0.175
TTM0.6005Y0.500+0.100
5Y0.50010Y0.377+0.123
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.7380.332+0.406
TTM0.6000.334+0.266
YOY0.4260.268+0.158
5Y0.5000.366+0.134
10Y0.3770.390-0.013
1.4.2. Debt to Equity Ratio

Measures if Xbrane is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Xbrane to the Biotechnology industry mean.
  • A Debt to Equity ratio of 281.4% means that company has kr2.81 debt for each kr1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Xbrane Biopharma AB:

  • The MRQ is 2.814. The company is unable to pay all its debts with equity. -1
  • The TTM is 1.693. The company is just able to pay all its debts with equity.
Trends
Current periodCompared to+/- 
MRQ2.814TTM1.693+1.121
TTM1.693YOY0.746+0.947
TTM1.6935Y1.118+0.575
5Y1.11810Y0.808+0.310
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.8140.381+2.433
TTM1.6930.390+1.303
YOY0.7460.334+0.412
5Y1.1180.434+0.684
10Y0.8080.466+0.342

2. Market Valuation of Xbrane Biopharma AB

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every kr1 in earnings Xbrane generates.

  • Above 15 is considered overpriced but always compare Xbrane to the Biotechnology industry mean.
  • A PE ratio of -4.17 means the investor is paying kr-4.17 for every kr1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Xbrane Biopharma AB:

  • The EOD is -0.152. Based on the earnings, the company is expensive. -2
  • The MRQ is -4.173. Based on the earnings, the company is expensive. -2
  • The TTM is -44.662. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.152MRQ-4.173+4.021
MRQ-4.173TTM-44.662+40.489
TTM-44.662YOY-130.016+85.354
TTM-44.6625Y-96.191+51.529
5Y-96.19110Y-138.593+42.402
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.152-2.315+2.163
MRQ-4.173-2.560-1.613
TTM-44.662-2.664-41.998
YOY-130.016-4.122-125.894
5Y-96.191-6.258-89.933
10Y-138.593-6.108-132.485
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Xbrane Biopharma AB:

  • The EOD is -0.294. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -8.086. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -33.856. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.294MRQ-8.086+7.791
MRQ-8.086TTM-33.856+25.770
TTM-33.856YOY79.404-113.260
TTM-33.8565Y-361.295+327.440
5Y-361.29510Y-270.422-90.873
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.294-3.067+2.773
MRQ-8.086-3.251-4.835
TTM-33.856-3.545-30.311
YOY79.404-5.595+84.999
5Y-361.295-8.315-352.980
10Y-270.422-8.708-261.714
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Xbrane is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 15.35 means the investor is paying kr15.35 for each kr1 in book value.

Let's take a look of the Price to Book Ratio trends of Xbrane Biopharma AB:

  • The EOD is 0.559. Based on the equity, the company is cheap. +2
  • The MRQ is 15.347. Based on the equity, the company is expensive. -2
  • The TTM is 37.293. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD0.559MRQ15.347-14.789
MRQ15.347TTM37.293-21.945
TTM37.293YOY56.719-19.426
TTM37.2935Y75.148-37.856
5Y75.14810Y82.677-7.529
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.5591.905-1.346
MRQ15.3472.111+13.236
TTM37.2932.095+35.198
YOY56.7192.836+53.883
5Y75.1483.443+71.705
10Y82.6773.794+78.883
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Xbrane Biopharma AB compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.608-0.241-60%-0.007-99%0.017-3724%0.018-3554%
Book Value Per Share--0.6521.207-46%1.439-55%1.060-39%0.711-8%
Current Ratio--1.4141.746-19%1.996-29%1.889-25%2.818-50%
Debt To Asset Ratio--0.7380.600+23%0.426+73%0.500+48%0.377+96%
Debt To Equity Ratio--2.8141.693+66%0.746+277%1.118+152%0.808+248%
Dividend Per Share----0%-0%-0%-0%
Eps---0.599-0.369-38%-0.164-73%-0.217-64%-0.128-79%
Free Cash Flow Per Share---0.309-0.403+30%-0.242-22%-0.260-16%-0.147-53%
Free Cash Flow To Equity Per Share---0.363-0.119-67%-0.100-72%-0.006-98%0.006-5698%
Gross Profit Margin--1.0001.0000%1.0000%1.0010%1.125-11%
Intrinsic Value_10Y_max---13.584--------
Intrinsic Value_10Y_min---11.725--------
Intrinsic Value_1Y_max---1.255--------
Intrinsic Value_1Y_min---1.233--------
Intrinsic Value_3Y_max---3.852--------
Intrinsic Value_3Y_min---3.676--------
Intrinsic Value_5Y_max---6.547--------
Intrinsic Value_5Y_min---6.070--------
Market Cap95715622.912-2647%2629550080.00013167472025.600-80%21404537651.200-88%18497150624.522-86%14032243632.139-81%
Net Profit Margin---2.355-1.615-31%-3.272+39%-8.418+257%-8.756+272%
Operating Margin---1.244-1.429+15%-3.210+158%-8.277+565%-13.854+1013%
Operating Ratio--2.2442.359-5%4.099-45%8.660-74%9.290-76%
Pb Ratio0.559-2647%15.34737.293-59%56.719-73%75.148-80%82.677-81%
Pe Ratio-0.152+96%-4.173-44.662+970%-130.016+3016%-96.191+2205%-138.593+3221%
Price Per Share0.364-2647%10.00050.075-80%81.400-88%70.343-86%53.364-81%
Price To Free Cash Flow Ratio-0.294+96%-8.086-33.856+319%79.404-110%-361.295+4368%-270.422+3244%
Price To Total Gains Ratio-0.599+96%-16.44327.393-160%-401.461+2342%-161.176+880%-48672.225+295913%
Quick Ratio--0.4180.824-49%1.038-60%1.066-61%1.943-78%
Return On Assets---0.241-0.128-47%-0.066-73%-0.110-54%-0.102-58%
Return On Equity---0.919-0.388-58%-0.113-88%-0.252-73%-0.193-79%
Total Gains Per Share---0.608-0.241-60%-0.007-99%0.017-3724%0.018-3554%
Usd Book Value--15625752.00028955680.800-46%34510764.000-55%25418712.240-39%17042720.295-8%
Usd Book Value Change Per Share---0.055-0.022-60%-0.001-99%0.002-3724%0.002-3554%
Usd Book Value Per Share--0.0590.110-46%0.131-55%0.097-39%0.065-8%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.055-0.034-38%-0.015-73%-0.020-64%-0.012-79%
Usd Free Cash Flow---7414742.400-9654637.200+30%-5792180.400-22%-6231189.840-16%-3517845.880-53%
Usd Free Cash Flow Per Share---0.028-0.037+30%-0.022-22%-0.024-16%-0.013-53%
Usd Free Cash Flow To Equity Per Share---0.033-0.011-67%-0.009-72%-0.001-98%0.001-5698%
Usd Market Cap8729264.810-2647%239814967.2961200873448.735-80%1952093833.789-88%1686940136.956-86%1279740619.251-81%
Usd Price Per Share0.033-2647%0.9124.567-80%7.424-88%6.415-86%4.867-81%
Usd Profit---14367009.600-8849706.000-38%-3926752.800-73%-5188650.720-64%-3069545.509-79%
Usd Revenue--6100732.8005441995.200+12%1313690.400+364%1459405.200+318%1125811.252+442%
Usd Total Gains Per Share---0.055-0.022-60%-0.001-99%0.002-3724%0.002-3554%
 EOD+3 -5MRQTTM+8 -25YOY+8 -255Y+7 -2710Y+7 -27

3.2. Fundamental Score

Let's check the fundamental score of Xbrane Biopharma AB based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.152
Price to Book Ratio (EOD)Between0-10.559
Net Profit Margin (MRQ)Greater than0-2.355
Operating Margin (MRQ)Greater than0-1.244
Quick Ratio (MRQ)Greater than10.418
Current Ratio (MRQ)Greater than11.414
Debt to Asset Ratio (MRQ)Less than10.738
Debt to Equity Ratio (MRQ)Less than12.814
Return on Equity (MRQ)Greater than0.15-0.919
Return on Assets (MRQ)Greater than0.05-0.241
Total3/10 (30.0%)

3.3. Technical Score

Let's check the technical score of Xbrane Biopharma AB based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5038.808
Ma 20Greater thanMa 500.366
Ma 50Greater thanMa 1000.774
Ma 100Greater thanMa 2004.128
OpenGreater thanClose0.359
Total0/5 (0.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in SEK. All numbers in thousands.

Summary
Total Assets653,508
Total Liabilities482,173
Total Stockholder Equity171,335
 As reported
Total Liabilities 482,173
Total Stockholder Equity+ 171,335
Total Assets = 653,508

Assets

Total Assets653,508
Total Current Assets461,693
Long-term Assets191,815
Total Current Assets
Cash And Cash Equivalents 65,402
Net Receivables 71,178
Inventory 106,856
Other Current Assets 218,257
Total Current Assets  (as reported)461,693
Total Current Assets  (calculated)461,693
+/-0
Long-term Assets
Property Plant Equipment 88,200
Intangible Assets 99,670
Long-term Assets  (as reported)191,815
Long-term Assets  (calculated)187,870
+/- 3,945

Liabilities & Shareholders' Equity

Total Current Liabilities326,557
Long-term Liabilities155,616
Total Stockholder Equity171,335
Total Current Liabilities
Short-term Debt 75,871
Short Long Term Debt 62,500
Accounts payable 30,974
Other Current Liabilities 219,712
Total Current Liabilities  (as reported)326,557
Total Current Liabilities  (calculated)389,057
+/- 62,500
Long-term Liabilities
Long term Debt 112,897
Capital Lease Obligations 56,082
Long-term Liabilities Other 8
Long-term Liabilities  (as reported)155,616
Long-term Liabilities  (calculated)168,987
+/- 13,371
Total Stockholder Equity
Common Stock6,683
Retained Earnings -1,273,999
Accumulated Other Comprehensive Income 10,121
Other Stockholders Equity 1,428,530
Total Stockholder Equity (as reported)171,335
Total Stockholder Equity (calculated)171,335
+/-0
Other
Capital Stock6,683
Cash and Short Term Investments 65,402
Common Stock Shares Outstanding 262,932
Liabilities and Stockholders Equity 653,508
Net Debt 166,077
Net Invested Capital 346,732
Net Working Capital 135,136
Property Plant and Equipment Gross 117,594
Short Long Term Debt Total 231,479



Balance Sheet

Currency in SEK. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-31
> Total Assets 
6,689
0
0
76,488
75,331
150,799
140,487
131,119
118,110
111,097
119,468
117,576
110,960
130,131
126,540
275,129
252,885
294,165
455,189
406,410
338,940
311,354
437,524
316,083
463,763
473,754
383,804
696,994
688,427
675,729
683,696
582,458
690,515
650,920
998,710
890,818
653,508
653,508890,818998,710650,920690,515582,458683,696675,729688,427696,994383,804473,754463,763316,083437,524311,354338,940406,410455,189294,165252,885275,129126,540130,131110,960117,576119,468111,097118,110131,119140,487150,79975,33176,488006,689
   > Total Current Assets 
6,556
0
0
3,020
7,433
76,809
64,493
53,911
43,526
39,659
49,504
39,239
28,100
45,012
40,975
172,756
161,659
198,683
357,598
304,147
247,937
217,074
345,968
221,411
374,482
400,187
308,081
593,684
561,008
519,836
522,755
415,756
513,524
462,371
815,823
690,038
461,693
461,693690,038815,823462,371513,524415,756522,755519,836561,008593,684308,081400,187374,482221,411345,968217,074247,937304,147357,598198,683161,659172,75640,97545,01228,10039,23949,50439,65943,52653,91164,49376,8097,4333,020006,556
       Cash And Cash Equivalents 
6,201
0
0
2,815
2,688
68,610
56,694
43,923
31,338
22,456
32,365
23,624
7,903
18,930
19,255
64,311
100,972
44,317
171,410
162,195
164,197
84,470
232,506
123,768
243,139
239,244
129,332
383,435
295,180
301,459
250,085
165,235
193,994
118,746
315,640
167,284
65,402
65,402167,284315,640118,746193,994165,235250,085301,459295,180383,435129,332239,244243,139123,768232,50684,470164,197162,195171,41044,317100,97264,31119,25518,9307,90323,62432,36522,45631,33843,92356,69468,6102,6882,815006,201
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
17,071
47,779
26,902
7,658
75,172
9,028
31,593
26,167
41,891
14,130
59,398
4,283
47,456
17,651
404,975
62,235
71,178
71,17862,235404,97517,65147,4564,28359,39814,13041,89126,16731,5939,02875,1727,65826,90247,77917,07100000000000000000000
       Other Current Assets 
355
0
0
206
4,585
5,186
4,994
7,118
9,691
14,941
15,521
14,344
17,132
22,762
17,535
105,794
55,162
145,454
176,233
131,850
83,740
132,604
113,462
97,643
131,343
160,943
178,749
210,249
265,828
1
1
246,238
221,814
272,239
-1
326,857
218,257
218,257326,857-1272,239221,814246,23811265,828210,249178,749160,943131,34397,643113,462132,60483,740131,850176,233145,45455,162105,79417,53522,76217,13214,34415,52114,9419,6917,1184,9945,1864,58520600355
   > Long-term Assets 
133
0
0
73,468
67,897
73,990
75,360
76,574
74,584
71,438
69,964
78,337
82,860
85,119
85,565
102,373
91,226
95,482
97,591
102,263
91,003
94,280
91,556
94,673
89,281
73,566
75,723
103,310
127,418
155,893
160,940
166,702
176,990
188,549
182,887
200,780
191,815
191,815200,780182,887188,549176,990166,702160,940155,893127,418103,31075,72373,56689,28194,67391,55694,28091,003102,26397,59195,48291,226102,37385,56585,11982,86078,33769,96471,43874,58476,57475,36073,99067,89773,46800133
       Property Plant Equipment 
133
0
0
9,623
10,024
15,037
16,126
17,184
16,581
15,349
14,782
15,373
18,569
18,162
17,983
17,553
16,745
20,266
21,502
25,163
16,208
15,083
16,835
15,783
14,134
60,796
63,044
71,809
73,801
71,564
71,709
73,685
70,782
76,779
72,445
94,446
88,200
88,20094,44672,44576,77970,78273,68571,70971,56473,80171,80963,04460,79614,13415,78316,83515,08316,20825,16321,50220,26616,74517,55317,98318,16218,56915,37314,78215,34916,58117,18416,12615,03710,0249,62300133
       Goodwill 
0
0
0
0
0
0
0
0
0
47
0
55,712
57,360
59,942
60,689
59,950
59,838
60,693
61,485
62,479
60,760
64,543
61,033
61,386
58,453
0
0
0
0
0
0
0
0
0
0
0
0
00000000000058,45361,38661,03364,54360,76062,47961,48560,69359,83859,95060,68959,94257,36055,712047000000000
       Intangible Assets 
0
0
0
0
0
58,953
59,234
59,390
57,368
55,455
54,547
6,617
6,297
6,381
6,258
5,983
5,773
5,653
5,522
5,403
5,053
5,153
4,669
4,492
4,083
0
0
26,922
49,672
79,604
85,286
89,071
101,995
107,825
106,496
0
99,670
99,6700106,496107,825101,99589,07185,28679,60449,67226,922004,0834,4924,6695,1535,0535,4035,5225,6535,7735,9836,2586,3816,2976,61754,54755,45557,36859,39059,23458,95300000
       Other Assets 
0
0
0
0
0
0
151,354
153,782
149,168
142,877
0
0
0
0
0
0
0
0
0
0
14,035
14,654
13,688
17,503
16,693
147,133
12,679
31,501
1
84,329
1
3,946
1
3,945
1
0
0
0013,94513,946184,329131,50112,679147,13316,69317,50313,68814,65414,0350000000000142,877149,168153,782151,354000000
> Total Liabilities 
391
0
0
20,501
27,821
18,124
13,996
13,116
10,809
14,337
13,896
12,019
22,555
46,501
70,945
160,597
169,815
193,047
167,497
164,691
154,617
171,855
246,177
181,107
206,055
265,384
234,065
234,563
256,686
279,480
317,962
255,699
265,627
283,515
598,722
559,560
482,173
482,173559,560598,722283,515265,627255,699317,962279,480256,686234,563234,065265,384206,055181,107246,177171,855154,617164,691167,497193,047169,815160,59770,94546,50122,55512,01913,89614,33710,80913,11613,99618,12427,82120,50100391
   > Total Current Liabilities 
391
0
0
14,618
23,405
13,228
9,049
8,105
5,884
9,477
9,022
7,296
17,892
21,672
31,090
147,181
161,382
136,942
155,177
148,584
139,615
156,758
232,136
167,426
188,993
216,254
190,996
194,882
219,667
245,054
284,256
224,300
236,569
253,177
410,189
393,525
326,557
326,557393,525410,189253,177236,569224,300284,256245,054219,667194,882190,996216,254188,993167,426232,136156,758139,615148,584155,177136,942161,382147,18131,09021,67217,8927,2969,0229,4775,8848,1059,04913,22823,40514,61800391
       Short-term Debt 
0
0
0
0
0
0
0
0
0
1,098
0
0
0
0
0
45,593
45,562
2,015
2,470
3,284
3,156
3,063
2,947
2,665
2,265
6,995
6,940
7,043
7,905
8,022
8,895
9,028
9,162
10,008
71,794
76,118
75,871
75,87176,11871,79410,0089,1629,0288,8958,0227,9057,0436,9406,9952,2652,6652,9473,0633,1563,2842,4702,01545,56245,593000001,098000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
12
0
0
0
0
0
0
0
0
0
0
0
0
0
62,012
62,500
62,500
62,50062,50062,01200000000000001200000000000000000000
       Accounts payable 
114
0
0
4,463
4,763
5,621
3,129
3,251
2,364
5,797
5,972
3,538
10,541
14,441
14,304
47,255
30,908
36,227
36,467
18,818
21,097
43,650
36,167
16,111
29,546
49,339
21,370
29,157
41,393
23,082
53,050
30,615
23,297
40,008
34,247
36,497
30,974
30,97436,49734,24740,00823,29730,61553,05023,08241,39329,15721,37049,33929,54616,11136,16743,65021,09718,81836,46736,22730,90847,25514,30414,44110,5413,5385,9725,7972,3643,2513,1295,6214,7634,46300114
       Other Current Liabilities 
277
0
0
10,155
18,642
7,607
5,920
4,855
3,521
2,581
3,049
3,758
7,351
7,231
16,786
54,333
84,912
98,700
116,240
126,482
115,362
110,045
193,022
148,650
157,182
159,920
162,686
158,682
168,594
213,950
222,311
184,657
68,047
87,561
2,934
5,295
219,712
219,7125,2952,93487,56168,047184,657222,311213,950168,594158,682162,686159,920157,182148,650193,022110,045115,362126,482116,24098,70084,91254,33316,7867,2317,3513,7583,0492,5813,5214,8555,9207,60718,64210,15500277
   > Long-term Liabilities 
0
0
0
5,883
4,417
4,896
4,947
5,010
4,924
4,860
4,874
4,723
4,663
24,829
39,855
13,416
8,433
56,105
12,320
16,107
15,002
15,097
14,041
13,681
17,062
49,130
43,069
39,681
37,019
34,426
33,706
31,399
29,058
30,338
188,533
166,035
155,616
155,616166,035188,53330,33829,05831,39933,70634,42637,01939,68143,06949,13017,06213,68114,04115,09715,00216,10712,32056,1058,43313,41639,85524,8294,6634,7234,8744,8604,9245,0104,9474,8964,4175,883000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,419
3,995
40,793
39,019
37,219
36,476
34,426
33,706
31,399
29,058
30,338
28,099
0
0
0028,09930,33829,05831,39933,70634,42636,47637,21939,01940,7933,9954,41900000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
8,721
9,453
9,124
9,262
13,067
8,337
4,050
2,462
-1
0
0
0
0
0
14,982
0
0
0014,98200000-12,4624,0508,33713,0679,2629,1249,4538,72100000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
5,053
5,153
4,669
4,492
4,083
0
0
26,922
49,672
79,604
0
0
0
0
106,496
0
0
00106,496000079,60449,67226,922004,0834,4924,6695,1535,05300000000000000000000
> Total Stockholder Equity
6,298
0
0
55,987
47,509
132,675
126,491
118,003
107,301
96,760
105,572
105,557
88,405
83,630
55,595
114,532
83,070
101,118
287,692
241,719
184,323
139,499
191,347
134,976
257,708
208,370
149,739
462,431
431,741
396,249
365,734
326,759
424,888
367,405
399,988
331,258
171,335
171,335331,258399,988367,405424,888326,759365,734396,249431,741462,431149,739208,370257,708134,976191,347139,499184,323241,719287,692101,11883,070114,53255,59583,63088,405105,557105,57296,760107,301118,003126,491132,67547,50955,987006,298
   Common Stock
100
0
0
101
500
1,036
1,036
1,036
1,066
1,066
1,333
1,336
1,335
1,335
1,419
1,419
1,419
1,419
2,847
3,456
3,456
3,456
4,322
4,322
4,977
4,977
4,982
5,614
5,614
5,614
5,637
5,640
6,166
6,166
6,550
6,665
6,683
6,6836,6656,5506,1666,1665,6405,6375,6145,6145,6144,9824,9774,9774,3224,3223,4563,4563,4562,8471,4191,4191,4191,4191,3351,3351,3361,3331,0661,0661,0361,0361,03650010100100
   Retained Earnings -1,273,999-1,116,465-1,035,235-944,224-885,827-825,094-783,210-749,435-713,313-680,842-635,373-576,205-524,938-461,885-404,142-322,827-273,941-218,014-185,615-141,216-107,903-75,480-135,576-103,583-94,667-75,593-77,807-68,693-56,314-46,214-36,113-28,556-23,026-17,69500-11,181
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
448,089
448,331
584,369
585,343
773,724
774,395
775,665
1,132,678
1,134,276
1,134,156
1,135,105
1,136,399
1,294,227
1,294,214
1,414,140
0
0
001,414,1401,294,2141,294,2271,136,3991,135,1051,134,1561,134,2761,132,678775,665774,395773,724585,343584,369448,331448,08900000000000000000000
   Treasury Stock0000000000000000000000000000000000000
   Other Stockholders Equity 
17,379
0
0
73,581
70,035
160,194
161,568
163,181
162,550
164,387
182,047
179,814
181,737
185,878
189,752
188,593
189,554
240,915
470,460
456,277
454,808
458,870
591,167
592,539
777,669
779,598
780,130
1,137,659
1,139,440
1,140,070
1,143,307
1,146,213
1,294,227
1,294,215
1,414,140
1,428,464
1,428,530
1,428,5301,428,4641,414,1401,294,2151,294,2271,146,2131,143,3071,140,0701,139,4401,137,659780,130779,598777,669592,539591,167458,870454,808456,277470,460240,915189,554188,593189,752185,878181,737179,814182,047164,387162,550163,181161,568160,19470,03573,5810017,379



Balance Sheet

Currency in SEK. All numbers in thousands.




Cash Flow

Currency in SEK. All numbers in thousands.




Income Statement

Currency in SEK. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue238,729
Cost of Revenue-224,774
Gross Profit13,95513,955
 
Operating Income (+$)
Gross Profit13,955
Operating Expense-324,381
Operating Income-310,426-310,426
 
Operating Expense (+$)
Research Development305,783
Selling General Administrative42,508
Selling And Marketing Expenses0
Operating Expense324,381348,291
 
Net Interest Income (+$)
Interest Income2,407
Interest Expense-137
Other Finance Cost-3,692
Net Interest Income5,962
 
Pretax Income (+$)
Operating Income-310,426
Net Interest Income5,962
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-322,028-298,824
EBIT - interestExpense = -310,563
-322,028
-388,035
Interest Expense137
Earnings Before Interest and Taxes (EBIT)-310,426-321,891
Earnings Before Interest and Taxes (EBITDA)-288,993
 
After tax Income (+$)
Income Before Tax-322,028
Tax Provision-0
Net Income From Continuing Ops-284,719-322,028
Net Income-388,172
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses549,155
Total Other Income/Expenses Net-11,602-5,962
 

Technical Analysis of Xbrane
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Xbrane. The general trend of Xbrane is BEARISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Xbrane's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-100.0%) Bearish trend (100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Xbrane Biopharma AB.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 0.427 < 1.994 < 3.45.

The bearish price targets are: 0.238 > 0.2204 > 0.2204.

Tweet this
Xbrane Biopharma AB Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Xbrane Biopharma AB. The current mas is .

The long score for the Moving Averages is 0/14.
The longshort score for the Moving Averages is -14/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Xbrane Biopharma AB Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Xbrane Biopharma AB. The current macd is -0.19799382.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Xbrane price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Xbrane. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Xbrane price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Xbrane Biopharma AB Daily Moving Average Convergence/Divergence (MACD) ChartXbrane Biopharma AB Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Xbrane Biopharma AB. The current adx is 7.7863269.

The long score for the Directional Movement Index (DMI) is 1/7.
The longshort score for the Directional Movement Index (DMI) is 1/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Xbrane shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Xbrane Biopharma AB Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Xbrane Biopharma AB. The current sar is 1.63104534.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Xbrane Biopharma AB Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Xbrane Biopharma AB. The current rsi is 38.81. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending up: The RSI is trending up. +1
Xbrane Biopharma AB Daily Relative Strength Index (RSI) ChartXbrane Biopharma AB Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Xbrane Biopharma AB. The current phase is Correction in bear market.

The long score for the Stochastic Oscillator is 4/6.
The longshort score for the Stochastic Oscillator is 4/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Xbrane price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Xbrane Biopharma AB Daily Stochastic Oscillator ChartXbrane Biopharma AB Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Xbrane Biopharma AB. The current cci is -13.40701495.

Xbrane Biopharma AB Daily Commodity Channel Index (CCI) ChartXbrane Biopharma AB Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Xbrane Biopharma AB. The current cmo is -17.60714582.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Xbrane Biopharma AB Daily Chande Momentum Oscillator (CMO) ChartXbrane Biopharma AB Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Xbrane Biopharma AB. The current willr is -41.44736842.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Xbrane is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Xbrane Biopharma AB Daily Williams %R ChartXbrane Biopharma AB Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Xbrane Biopharma AB.

Xbrane Biopharma AB Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Xbrane Biopharma AB. The current atr is 0.15701494.

Xbrane Biopharma AB Daily Average True Range (ATR) ChartXbrane Biopharma AB Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Xbrane Biopharma AB. The current obv is 61,854,910.

Xbrane Biopharma AB Daily On-Balance Volume (OBV) ChartXbrane Biopharma AB Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Xbrane Biopharma AB. The current mfi is 69.36.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Xbrane Biopharma AB Daily Money Flow Index (MFI) ChartXbrane Biopharma AB Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Xbrane Biopharma AB.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-27STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-28RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-30STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-04STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-08STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-11STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-13SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2023-12-14MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2023-12-15STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-18WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-20MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2023-12-21RSI LONG ENTRY SHORT CLOSE30 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-22CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-27STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-29STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-03STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-10SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-01-11WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-15CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-16MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-17STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-19STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-22MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-29STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-30STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-07MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-09MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-02-14SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-15CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-16STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-02-19SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-21STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-23RSI LONG ENTRY SHORT CLOSE30 crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-26MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-02-27STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-29RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-05DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-06WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-11CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-12WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-14STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-18CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-20STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-25DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-04DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-11STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-17STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-18STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

Xbrane Biopharma AB Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Xbrane Biopharma AB based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5038.808
Ma 20Greater thanMa 500.366
Ma 50Greater thanMa 1000.774
Ma 100Greater thanMa 2004.128
OpenGreater thanClose0.359
Total0/5 (0.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Xbrane with someone you think should read this too:
  • Are you bullish or bearish on Xbrane? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Xbrane? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Xbrane Biopharma AB

I send you an email if I find something interesting about Xbrane Biopharma AB.


Comments

How you think about this?

Leave a comment

Stay informed about Xbrane Biopharma AB.

Receive notifications about Xbrane Biopharma AB in your mailbox!